Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats

Critical Care Medicine
Naoaki HaradaMitsuhiro Uchiba

Abstract

To examine whether dalteparin, a low molecular weight heparin, prevents hepatic damage by inhibiting leukocyte activation, we analyzed its effect on ischemia/reperfusion (I/R) injury of rat liver in which activated leukocytes play a critical role. Prospective, randomized, controlled study. Research laboratory at a university medical center. Male Wistar rats weighing 220-280 g. Hepatic damage was evaluated by changes in serum transaminase concentrations after I/R. Coagulation abnormalities were evaluated by changes in serum concentrations of fragment E of fibrin and fibrinogen degradation products after I/R. Hepatic tissue blood flow was measured by laser-Doppler flow meter. Hepatic edema was evaluated by determination of the change in the wet/dry tissue weight ratio. Rats were intravenously injected with dalteparin or unfractionated heparin (300 units/kg) and subcutaneously injected with DX9056a, a selective inhibitor of activated factor X (3 mg/kg). To determine whether dalteparin inhibits leukocyte activation, we examined the effect of dalteparin on hepatic concentrations of interleukin-12, tumor necrosis factor-alpha, and hepatic myeloperoxidase activity after I/R in vivo. In addition, we examined increases in tumor necrosis...Continue Reading

References

Oct 1, 1992·The Journal of Clinical Investigation·H U SimonK A Siminovitch
Dec 1, 1989·The Journal of Clinical Investigation·J S WarrenP A Ward
Dec 1, 1985·Transplantation·S L AtallaJ P Cederna
Feb 1, 1986·The Journal of Surgical Research·H HayashiA E Baue
Dec 1, 1985·The Journal of Surgical Research·G A KellerR L Simmons
May 1, 1985·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·A K SinhaR W Colman
Feb 1, 1996·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·F KhalfiJ C Cazin
Nov 1, 1996·Critical Care Medicine·S KushimotoK Takatsuki
Nov 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A B LentschM J Edwards
Feb 26, 2000·Immunology Today·J D SedgwickH Körner
Nov 9, 2000·American Journal of Respiratory and Critical Care Medicine·P EnkhbaatarY Yamaguchi
May 6, 2004·The Journal of Surgical Research·Yuji TakamatsuMasao Tanaka
Jul 13, 2004·American Journal of Physiology. Gastrointestinal and Liver Physiology·Kenji OkajimaMasakazu Mori
May 28, 2005·Transplantation Proceedings·J W Kupiec-Weglinski, R W Busuttil

❮ Previous
Next ❯

Citations

Aug 21, 2013·Transplantation Proceedings·M Z AkhtarP J Friend
Jul 16, 2011·The Veterinary Clinics of North America. Small Animal Practice·Benjamin M Brainard, Andrew J Brown
Jun 23, 2009·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Jiro OmataKazuo Hase
Aug 21, 2009·Journal of Veterinary Emergency and Critical Care·Geoffroy de la Rebière de PouyadeDidier D A Serteyn
Dec 12, 2017·Toxicological Sciences : an Official Journal of the Society of Toxicology·Anna K KopecJames P Luyendyk
Dec 19, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zhao ShanCynthia Ju
Aug 31, 2016·The American Journal of Tropical Medicine and Hygiene·Helton C Santiago, Thomas B Nutman
Feb 14, 2020·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·K-H LinC-Y Huang
May 29, 2015·World Journal of Hepatology·Abdullah A AlgarniSimon R Bramhall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.